You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. The assets of failed DNA testing firm 23andMe are being bought for $256 million. Biotechnology firm ...

23andMe is in trouble. Once a hot Silicon Valley startup, the genetic testing company has been in free fall since a major data breach last year that affected roughly half of its customers. The ...

Anne Wojcicki, once the face of biotech’s consumer revolution, holding a Breakthrough Prize. Years later, 23andMe has filed for bankruptcy—taking 99.8 percent of its value and the genetic data of 15 ...

Regeneron Pharmaceuticals has agreed to acquire nearly all of 23andMe’s assets for $256 million, including its genetic data, following a bankruptcy auction. The deal still needs to be approved by the ...

Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. Biotech ...

23andMe will keep offering customers its DNA testing services after being bought out of bankruptcy. New York-based biotech company Regeneron Pharmaceuticals announced an agreement on Monday to ...

What have we learned from the era of special purpose acquisition companies? They emerged quickly during the pandemic, seemingly out of nowhere, when 0 percent interest rates prevailed. Today the ...

David Siffert, legal director at S.T.O.P., discusses 23andMe’s possible bankruptcy along with the potential legal fallout and the privacy threat it poses to our genetic data. By now, multiple sources ...

Regeneron Pharmaceuticals will acquire 23andMe's assets for $256 million, both companies said. 23andMe filed for Chapter 11 bankruptcy earlier this year. The DNA testing company has faced major ...